Nilanjan Ghosh, MD, PhD, on Paving the Way for CAR T Therapies in Lymphomas

Video

The chief of the lymphoma division and oncologist at Levine Cancer Institute discussed work that needs to be done to support the use of CAR T therapy.

“Some work that needs to be done would be development of products which have lower manufacturing time, another would be a more rapid process for financial clearance for commercial parties. We need to understand that the disease is aggressive in many cases, and we just can't wait 4 weeks to get clearance. Another thing would be building relationships with physicians and educating them about indications for CAR T.”

The last few years have seen chimeric antigen receptor (CAR) T-cell therapy approvals in hematologic malignancies including lisocabtagenemaraleucel (Breyanzi), axicabtagenecliolecleucel (Yescarta), brexucabtageneautoleucel (Tecartus) and ciltacabtageneautoleucel (Carvykti). With these approvals, clinicians are beginning to see the long-term impact of these treatments in the clinic

Nilanjan Ghosh, MD, PhD, chief of the lymphoma division and oncologist at Levine Cancer Institute, is one such clinician with first-hand experience with cell therapies in lymphoma. CGTLive spoke to Ghosh to learn more about work that needs to be done to support the growing prominence of CAR T-cell therapies in cancer treatment and future therapies to come to market. He also noted some questions that remain to be researched with these cell therapies.

Related Videos
Michael Kelly, PhD
Alan Beggs, PhD
John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Jeffrey Chamberlain, PhD
Brian Shaffer, MD
Arshad Khanani, MD
John Ligon, MD, an assistant professor in the department of pediatrics at the University of Florida College of Medicine
Carrie Miceli, PhD, a professor of microbiology, immunology, and molecular genetics at University of California, Los Angeles (UCLA)
© 2024 MJH Life Sciences

All rights reserved.